Welcome to our dedicated page for Sotera Health news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health stock.
Sotera Health Company provides sterilization solutions, lab testing and advisory services for the healthcare industry through Sterigenics, Nordion and Nelson Labs. News about SHC commonly covers quarterly and annual operating results, constant-currency revenue trends, Adjusted EBITDA commentary and outlook updates across those businesses.
Recurring company developments also include segment performance in outsourced terminal sterilization, irradiation services and laboratory testing, as well as governance changes, board committee assignments and capital-structure activity involving its Nasdaq-listed common stock. Sterigenics uses gamma irradiation, EO processing and E-beam irradiation for medical device, pharmaceutical, food safety and other application markets.
Sotera Health Company (SHC) announced Q3 2022 financial results, showcasing a 10% increase in net revenues to $249 million, with adjusted EBITDA rising 7.3% to $125 million. Net income slightly decreased to $25 million from $27 million in Q3 2021. The company adjusted its full-year revenue guidance to $995-$1,005 million and EBITDA to $500-$510 million, reflecting macroeconomic pressures, including foreign exchange impacts. Sotera emphasized ongoing capacity expansion and operational excellence while announcing the appointment of Alex Dimitrief as General Counsel, effective November 1.
Sotera Health Company (Nasdaq: SHC) has appointed Alex Dimitrief as its new Senior Vice President and General Counsel. Dimitrief brings over 40 years of experience from General Electric and Kirkland & Ellis LLP, where he specialized in litigation, M&A, and regulatory affairs. He succeeds Terry Hammons and will report directly to CEO Michael B. Petras, Jr.. Dimitrief's extensive leadership in complex legal matters is expected to enhance Sotera's mission-critical operations in sterilization solutions and advisory services.
Sotera Health Company (Nasdaq: SHC) announced its plan to release third-quarter financial results for the period ending September 30, 2022, before market open on November 2, 2022. Following this release, a conference call will take place at 9:00 a.m. Eastern Time to discuss the company’s operating highlights and financial outcomes. Investors can access the call via webcast on the company's website. Sotera Health provides vital sterilization solutions and lab testing services to the healthcare industry.
Sotera Health Company (SHC) reported Q2 2022 net revenues of $267 million, a 6% increase from Q2 2021. Net income was $30 million or $0.11 per diluted share, down from $43 million or $0.15 per share in the prior year. Adjusted EBITDA rose 1% to $136 million. The company narrowed its 2022 revenue outlook to $1.0 to $1.022 billion and adjusted EBITDA to $515 to $525 million. Segment performance showed mixed results, with Sterigenics up 8.7% while Nelson Labs faced declines.
Sotera Health Company (Nasdaq: SHC) has appointed Michael F. Biehl as the new Interim Chief Financial Officer effective July 20, 2022, following Scott Leffler's departure. Biehl brings nearly 20 years of experience in public company CFO roles. Sotera Health plans to release its second-quarter financial results for the period ending June 30, 2022, on August 4, 2022, prior to the market open, followed by a conference call at 9:00 a.m. ET to discuss operational highlights and financial metrics.
Sotera Health Company (NASDAQ: SHC) announced the departure of CFO Scott Leffler after over five years, effective August 12, 2022, as he relocates to Florida for a new role. The search for a permanent replacement is underway. Leffler's exit is not linked to any operational issues within the company. CEO Michael B. Petras, Jr. expressed gratitude for Leffler's contributions and confidence in the company's future growth, emphasizing its commitment to the mission of safeguarding global health.
Sterigenics has officially launched operations at its newly expanded electron beam (E-beam) facility in Columbia City, Indiana. This expansion aims to enhance sterilization services for medical devices and pharmaceutical products, meeting growing customer demands. The installation of a new E-beam accelerator increases sterilization capacity, ensuring safety for healthcare products. Notably, Sterigenics emphasizes improved productivity, reliability, and safety as part of this facility's upgrade, aligning with its mission of Safeguarding Global Health.
Sotera Health Company (Nasdaq: SHC) reported Q1 2022 net revenues of $237 million, a 12% increase from Q1 2021. Net income rose to $31 million or $0.11 per share, compared to $11 million or $0.04 per share last year. Adjusted EBITDA reached $115 million, up by 10%. The company reaffirmed its 2022 financial outlook, expecting net revenues between $1.0 billion and $1.03 billion. Despite challenges like the Omicron surge and geopolitical issues, Sotera Health emphasized strong execution and strategic capacity building.
Sotera Health Company (Nasdaq: SHC) plans to release its financial results for Q1 2022 on May 5, 2022, before market open. A conference call to discuss the results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 1-866-777-2509 from the U.S. or 1-412-317-5413 internationally. A live webcast of the call will be available on the company’s Investor Relations website, with a replay accessible later on the same day.
Sotera Health Company (Nasdaq: SHC) has launched the Sotera Health Academy, a new educational platform offering over 100 hours of curated content aimed at supporting MedTech and Pharmaceutical customers. The Academy features more than 150 resources, including webinars and eBooks, created by industry experts from Nelson Labs, Sterigenics, and Nordion. This initiative follows Sotera's acquisition of Regulatory Compliance Associates, enhancing the platform's offerings. The Academy aims to help manufacturers navigate regulatory risks and accelerate product market entry.